Show/Hide Menu

Strengthening
the proprietary portfolio

MorphoSys is committed to broadening its portfolio of novel therapeutics and is looking to secure alliances along the different stages of drug development and in technology. Backed by a strong financial position with the mandate to invest in compound development, MorphoSys is striving to build the most valuable pipeline of biopharmaceuticals in the biotechnology industry.

Early-stage
therapeutic opportunities

Academic partners can receive broad access to MorphoSys’s Ylanthia technology to validate their portfolio of novel disease-related targets and generate therapeutic antibody candidates against them. In return, MorphoSys would receive the option to in-license and develop individual programs resulting from this work. Exciting new drug candidates may emerge from these partnerships, adding valuable assets to our pipeline. Recent alliances in this field include agreements with Temple University’s Moulder Center for Drug Discovery Research. MorphoSys’s ability to turn an in-licensed target into a valuable commercial opportunity for its academic collaborator and its shareholders is exemplified by the MOR103 program. Starting from an exclusive license and collaboration agreement with Melbourne University, the program was advanced by MorphoSys into phase 2 clinical development. Based on very promising proof-of-concept data, MorphoSys secured GlaxoSmithKline as a partner to bring the compound to the market globally.

Various biopharmaceutical companies such as Galapagos and Merck have decided to engage in even more comprehensive alliances with MorphoSys. These partnerships start with joint target validation and antibody generation at MorphoSys and result in drug programs that are co-developed into the clinic and potentially beyond. If beneficial for a potential partner, collaboration agreements can be further enhanced with an investment by MorphoSys as part of our Innovation Capital initiative.

Cancer

MorphoSys is developing three proprietary compounds in clinical trials and looking to expand its oncology portfolio.
More information

Immuno-oncology

MorphoSys is already working on a range of immune checkpoint targets, in partnered programs and for its own account.
More information

Inflammatory and autoimmune diseases

Antibody drugs have transformed inflammatory and autoimmune disease treatments. We are committed to continue this success.
More information

GPCR

We provide a complete solution for the challenge of consistently generating efficacious antibodies against GPCRs.
More information

Lanthipeptides

MorphoSys uses the highly target selective and stable lanthipeptides for drug discovery in various indications.
More information

Mid-stage
therapeutic opportunities

MorphoSys is looking to in-license targets and compounds, primarily in the core areas of its proprietary development activities: cancer and inflammatory and autoimmune diseases. Our main focus lies on partnerships related to antibodies, other protein scaffolds and peptides preferably in late preclinical or early clinical stages. MorphoSys is the ideal partner to quickly advance such compounds to the market and provides a high level of attention to each single partner and program. Successful alliances of this kind include the co-development and co-commercialization agreement with Emergent BioSolutions in relation to the bi-specific prostate cancer compound MOR209/ES414 and the in-licensing of the Fc-enhanced cancer compound MOR208 from Xencor. An additional compound deriving from a co-development entered the clinical development stage in 2016. MOR106 was jointly discovered by MorphoSys and Galapagos under their collaboration, and has a novel mode of action with potential application in inflammation.

Late-stage
therapeutic opportunities

By joining forces with market-leading companies, we maximize the value of our pipeline. For example our antibody MOR103, has shown MorphoSys ability to take proprietary products from target discovery into clinical development and on to significant licensing agreements. MOR103 has been out-licensed to GlaxoSmithKline for further development and commercialization in rheumatoid arthritis and other inflammatory autoimmune diseases.

Our intention is to develop a leading portfolio of proprietary drug candidates, and to realize their full potential together with strong development and commercialization partners or on our own account. Decisions as to when and if alliances will be sought for our proprietary assets will be made on a case-by-case basis.

MOR208

MOR208 has been engineered to possess significantly enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thus improving a key mechanism for tumor cell killing and offering potential for enhanced efficacy compared to traditional antibodies for the treatment of cancer.

Further Information

MOR103/GSK3196165

MOR103 is a fully human HuCAL antibody directed against GM-CSF (granulocyte macrophage-colony stimulating factor). MOR103 is being developed in the area of inflammatory diseases, i.e. rheumatoid arthritis, where current treatment options are inadequate.

Further Information

MOR202

MOR202 is a fully human HuCAL antibody directed against CD38, a therapeutic target for the treatment of multiple myeloma (MM) and certain leukemias. 

Further Information

Technology
opportunities

MorphoSys is constantly looking to strengthen its technology platform. We are open to in-license and/or collaborate on complementary approaches with a focus on antibodies, antibody-like formats, scaffolds and therapeutic peptides. The Company’s core expertise in the intelligent design, generation and screening of diverse protein libraries can be applied to various drug classes and approaches. If beneficial for a potential partner, collaboration agreements can be further enhanced with an investment by MorphoSys as part of our Innovation Capital initiative. MorphoSys's ability to advance a fledgling technology effort in collaboration with a start-up and establish a broader technology platform quickly is exemplified by our alliance with LanthioPharma to establish a broad therapeutic lantipeptide library. In May 2015, MorphoSys acquired Lanthio Pharma, complementing MorphoSys´s growing proprietary portfolio by promising lantipeptide drug candidates, including Lanthio Pharma´s lead candidate LP2 (now MOR107) which is being developed against diabetic nephropathie and fibrotic diseases.

Business Development

Dr. Barbara Krebs-Pohl

Senior Vice President, Head of Business Development

Phone: +49 (0)89 89927 453

Fax: +49 (0)89 89927 5453

Email Contact

Dr. Roshni Bhakta

Associate Director Business Development and Portfolio Management

Phone: +49 (0)89 89927 453

Fax: +49 (0)89 89927 5453

Email Contact

Dr. Anja Hanisch

Associate Director Business Development and Portfolio Management

Phone: +49 (0)89 89927 453

Fax: +49 (0)89 89927 5453

Email Contact

Please note: MorphoSys has a specific procedure for receiving and processing confidential or proprietary information from external sources. Please contact us to obtain the details of this procedure before sending any such information. For that reason, all unsolicited submissions of any kind will be treated as non-confidential and non-proprietary and MorphoSys may freely use any ideas, inventions or anything else contained in your submission.